Anika Therapeutics (Anika Therapeutics) COGS-to-Revenue : 0.39 (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics COGS-to-Revenue?

Anika Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $16.6 Mil. Its Revenue for the three months ended in Dec. 2023 was $43.0 Mil.

Anika Therapeutics's COGS to Revenue for the three months ended in Dec. 2023 was 0.39.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Anika Therapeutics's Gross Margin % for the three months ended in Dec. 2023 was 61.27%.

Anika Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Anika Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics COGS-to-Revenue Chart

Anika Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.25

0.47

0.44

0.40

0.38

Anika Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.39	0.40	0.35	0.40	0.39

Anika Therapeutics COGS-to-Revenue Calculation

Anika Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	63.574	/	166.662
	=	0.38

Anika Therapeutics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	16.642	/	42.971
	=	0.39

Anika Therapeutics (NAS:ANIK) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Anika Therapeutics's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	16.642 / 42.971
	=	61.27 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Anika Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Anika Therapeutics (Anika Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

AKP:Germany

Address

32 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.anika.com

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Executives

Anne Nunes	officer: SVP, Chief Operations Officer	32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti	director	600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran	officer: EVP, General Counsel, Corp Sec	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz	officer: EVP, CFO, Treasurer	C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land	director
Stephen Richard	director	C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop	officer: EVP Business Development	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung	officer: CFO	ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson	director	1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling	officer: President	501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767